Articles - 6bod mentioned but not cited (1)
- Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition. Beyett TS, Gan X, Reilly SM, Chang L, Gomez AV, Saltiel AR, Showalter HD, Tesmer JJG. Mol Pharmacol 94 1210-1219 (2018)
Reviews citing this publication (12)
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway. Ding C, Song Z, Shen A, Chen T, Zhang A. Acta Pharm Sin B 10 2272-2298 (2020)
- Signaling by cGAS-STING in Neurodegeneration, Neuroinflammation, and Aging. Paul BD, Snyder SH, Bohr VA. Trends Neurosci 44 83-96 (2021)
- S100 proteins as therapeutic targets. Bresnick AR. Biophys Rev 10 1617-1629 (2018)
- Essential Roles for the Non-Canonical IκB Kinases in Linking Inflammation to Cancer, Obesity, and Diabetes. Shin CH, Choi DS. Cells 8 E178 (2019)
- Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease. Dosanjh A, Won CY. Yale J Biol Med 93 759-763 (2020)
- Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors. Giraud F, Pereira E, Anizon F, Moreau P. Molecules 26 2696 (2021)
- The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Verzella D, Cornice J, Arboretto P, Vecchiotti D, Di Vito Nolfi M, Capece D, Zazzeroni F, Franzoso G. Biomedicines 10 2233 (2022)
- Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy. Zhang M, Zou Y, Zhou X, Zhou J. Front Immunol 13 954129 (2022)
- Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases. Seok JK, Kim M, Kang HC, Cho YY, Lee HS, Lee JY. Arch Pharm Res 46 500-534 (2023)
- Role of IKKε in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology. Xiao QA, He Q, Li L, Song Y, Chen YR, Zeng J, Xia X. Front Pharmacol 13 888588 (2022)
- Role of nucleic acid sensing in the pathogenesis of type 1 diabetes. Badal D, Sachdeva N, Maheshwari D, Basak P. World J Diabetes 12 1655-1673 (2021)
- Tetrazoles and Related Heterocycles as Promising Synthetic Antidiabetic Agents. Trifonov RE, Ostrovskii VA. Int J Mol Sci 24 17190 (2023)
Articles citing this publication (4)
- Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway. Xiong J, Guo G, Guo L, Wang Z, Chen Z, Nan Y, Cao Y, Li R, Yang X, Dong J, Jin X, Yang W, Huang Q. ACS Omega 6 4289-4299 (2021)
- Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes. Gan X, Wilson MW, Beyett TS, Wen B, Sun D, Larsen SD, Tesmer JJG, Saltiel AR, Showalter HD. J Labelled Comp Radiopharm 62 202-208 (2019)
- A concise synthesis of 3-substituted-7-amino-6-carboxyl-8-azachromones. Gan X, Showalter HD. Tetrahedron Lett 60 2035-2037 (2019)
- TRAF7 negatively regulates the RLR signaling pathway by facilitating the K48-linked ubiquitination of TBK1. Huang JP, Yang YX, Chen T, Wang DD, Li J, Xu LG. Virol Sin 38 419-428 (2023)